Pharming Group (PHAR) Q4 2025 earnings review
Profitability Reached, But Growth Faces Regulatory Speed Bumps
Pharming reached a critical inflection point in 2025: the company reversed its operating losses and generated robust positive cash flow. Total revenue surged 27% to US$376.1M, fueled by a 53% Q4 acceleration in Joenja sales and steady RUCONEST performance. However, FY26 revenue guidance implies a sharp deceleration to 8-13% growth. Combined with a recent FDA Complete Response Letter for Joenja's pediatric label and diagnostic bottlenecks, the path to maintaining high-double-digit growth has materially narrowed.
🐂 Bull Case
Pharming generated US$25.8M in operating profit and US$54.7M in operating cash flow in 2025, reversing negative figures from 2024. The core business is now entirely self-funding.
Joenja revenue accelerated significantly in Q4 (+53% YoY to US$19.8M), driven by a 25% increase in U.S. patients on paid therapy to 120.
🐻 Bear Case
FY26 revenue guidance of 8-13% marks a significant slowdown from 2025's 27% growth, indicating the initial surge of Joenja adoption may be normalizing.
A January 2026 FDA Complete Response Letter for pediatric Joenja, alongside slower-than-expected Variant of Uncertain Significance (VUS) patient reclassifications, pushes TAM expansion further into the future.
⚖️ Verdict: ⚪
Neutral. The transition to a profitable, cash-generating business is a massive de-risking event. However, the FDA's CRL for pediatric Joenja and the guided deceleration in FY26 revenue growth limit near-term upside until clinical pipeline catalysts hit in late 2026.
Key Themes
Joenja U.S. Commercial Acceleration
Joenja's U.S. rollout is visibly accelerating. Q4 revenue jumped 53% YoY to US$19.8M (compared to 29% for the full year). U.S. patients on paid therapy increased 25% to 120 by year-end, with 24 net new U.S. patients added in 2025 versus 16 in 2024. The U.S. remains the anchor, contributing 86% of global Joenja revenues.
FDA Roadblock for Pediatric Joenja
Management disclosed a Complete Response Letter (CRL) received on Jan 30, 2026, for the Joenja pediatric sNDA (ages 4-11). The FDA requires additional pharmacokinetic data and analytical batch testing clarification. While Pharming believes the issues are addressable, this definitively delays near-term access to the 52 identified U.S. patients in this age bracket.
VUS Reclassification is Proving Slower Than Expected
There are over 1,800 known U.S. patients with a Variant of Uncertain Significance (VUS) for APDS. Pharming previously hoped a June 2025 Columbia University study would quickly enable lab reclassifications. However, testing labs are requiring additional complementary evidence, forcing Pharming to plan new experiments. This represents a decelerating catalyst for patient identification.
RUCONEST Remains a Resilient Cash Cow
Despite competitive market dynamics in the HAE space, RUCONEST grew 9% YoY in Q4 and 26% for the full year, reaching a record US$317.9M. Growth was driven by a 20% FY increase in U.S. unit sales volume and a 6% increase in the physician prescriber base. The product's positioning for patients failing other on-demand therapies continues to hold stable.
Abliva Integration Modifies the Cost Structure
The acquisition of Abliva heavily impacted FY25 financials. While total R&D and SG&A rose, Pharming absorbed US$29.7M in Abliva-related expenses and a US$5.0M Joenja milestone. Despite this, they posted an operating profit. Stripping out one-offs, underlying operating expenses grew just 2% YoY, showing tight core cost controls.
Other KPIs
Reversing trend. Shifted dramatically from negative in FY24 to strongly positive in FY25. Total cash and marketable securities now sit at US$181.1M, giving management significant flexibility for M&A without immediate need for dilutive capital raises.
Stable. Gross profit grew 26% to US$330.6M. Cost of sales increased primarily due to higher unit volumes, increased Joenja royalties to Novartis (US$5.8M), and a US$5.0M Joenja sales milestone. Lower inventory impairment charges offset some of this pressure.
Accelerating. Intangibles more than doubled from US$61.0M in FY24, completely driven by the Abliva acquisition and the capitalization of intellectual property related to the napazimone (KL1333) program.
Guidance
Decelerating. Represents 8% to 13% YoY growth, a stark slowdown compared to 27% growth achieved in FY25. This likely reflects the delay in Joenja pediatric expansion and mature RUCONEST market dynamics.
Accelerating absolute spend (6% to 8% growth). Includes US$60M in incremental R&D to push the pipeline (particularly leniolisib Phase II and KL1333). Management expects to offset some of this with US$9M in structural G&A reductions.
Key Questions
Joenja Pediatric CRL Timeline
Regarding the additional PK data and analytical batch testing required by the FDA for pediatric Joenja: will generating this data require new trials, and realistically, what is the earliest anticipated resubmission date?
VUS Reclassification Bottleneck
With labs requiring 'additional complementary evidence' for VUS reclassification, what is the specific cost and time horizon for the new planned experiments, and how many of the 1,800+ VUS patients are modeled to convert in 2026?
Capital Allocation & M&A
With the business generating positive cash flow, you noted a continued focus on acquisitions. Will future M&A lean towards commercial-stage assets to boost near-term revenue growth, or early-clinical stage like Abliva?